Annual revenue rose from KRW 25.5 billion in 2022 to KRW 26.5 billion in 2023, up 4.1% year on year, then fell to KRW 21.5 billion in 2024, down 19.0%, and to KRW 14.5 billion in 2025, down 32.4%. 2023 was the largest year in the 2022 to 2025 span, and revenue has declined for two consecutive years since 2024.
Operating loss narrowed from KRW 2.62 billion in 2022 to KRW 1.72 billion in 2023, then widened to KRW 5.73 billion in 2024 and KRW 5.87 billion in 2025.
The operating margin deteriorated from -10.3% in 2022 and -6.5% in 2023 to -26.6% in 2024 and -40.4% in 2025 as losses grew while revenue shrank, which suggests fixed-cost burden rose relative to sales.
Net profit attributable to controlling shareholders turned positive at KRW 39.15 million in 2023 but was a loss of KRW 19.1 billion in 2024 and KRW 38.6 billion in 2025, two straight loss years.
Net income including non-controlling interests was a loss of KRW 20 billion in 2024 and KRW 37.7 billion in 2025, so the two measures differ.
Quarterly revenue peaked at KRW 3.79 billion in the first quarter of 2026 after KRW 3.51 billion in the fourth quarter of 2025, then fell to KRW 2.02 billion in the second quarter and KRW 961 million in the third quarter of 2026.
The fourth quarter of 2025 carried the largest losses in the period, with an operating loss of KRW 1.88 billion and a loss attributable to controlling shareholders of KRW 21.1 billion.
Press reports said the stakes in its medical device subsidiary and in the battery technology firm were impaired at end-2025, and how much of the fourth-quarter loss reflects these items needs confirmation from the periodic filings. Total liabilities at end-2025 were KRW 18.6 billion, and operating cash flow was negative KRW 5.18 billion.